Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod
Backing Comes Day After Pfizer's Paxlovid Green Light
Executive Summary
US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."
You may also be interested in...
Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.